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Summary 
Next generation sequencing technologies have enabled the transcriptome to be profiled at a 
previously unprecedented speed and depth. This yielded insights into fundamental 
transcriptomic processes such as gene transcription, RNA processing, and mRNA splicing. 
Immunoprecipitation-based transcriptomic methods such as individual nucleotide resolution 
crosslinking immunoprecipitation (iCLIP) have also allowed high-resolution analysis of the 
RNA interactions of a protein of interest, thus revealing new regulatory mechanisms. We 
and others have recently modified this method in order to profile RNA methylation, and we 
refer to this customised technique as methylation-iCLIP (miCLIP). Variants of miCLIP have 
been used to map the methyl-5-cytosine (m5C) or methyl-6-adenosine (m6A) modification 
at nucleotide resolution in the human transcriptome. Here we describe the m5C-miCLIP 
protocol and discuss how it yields the nucleotide-resolution RNA modification maps. Finally, 
we describe insights into the influence of RNA sequence and structure on the addition of 
covalent RNA modifications that were gained from miCLIP studies, and how these have 
contributed to the new field of molecular genetics research coined ‘epitranscriptomics’. 
 
 
 
 
 
 
 
 
 
 
 
 
1 Introduction 
1.1 RNA Methylation and the development of transcriptomic techniques to detect their 
occurrence at nucleotide resolution 
Covalent modifications to cellular RNA molecules can occur both on the sugar-phosphate 
RNA backbone as well as on nucleobases and can include those that occur at internal 
positions as well as those present on 5’ or 3’ termini. A few of these such as the m7G cap 
that is ubiquitously present on the 5’ terminus of cellular mRNAs have been well 
characterised. However it is known that well over a hundred types of modified RNA 
nucleobases can exist, though the characterisation of these have been hampered largely 
due to a lack of suitable techniques to detect their sequence-specific occurrence. For 
example, it had for decades been suspected that internal methyl-6-adenosine (m6A) and 
methyl-5-cytosine (m5C) base methylations may be a common occurrence on mRNAs in 
mammalian cells (1), but it was only much more recently that the development of refined 
transcriptomic approaches allowed these modifications to be comprehensively mapped 
(2,3,4,5,6) thus greatly aiding efforts to investigate their mechanistic roles (6,7,8,9,10).  
Previous important studies were also critical for setting the stage for the recent flurry of 
activity in the field. It had been shown that a multiprotein complex, which includes the 
METTL3 and METTL14 subunits, catalyses the formation of m6A in RNA (11) and that an 
additional enzyme encoded by the FTO gene can remove these methylation marks (12). The 
latter finding was particularly exciting as it suggested that these RNA methylation events 
could be dynamically controlled during the execution of important biological processes. Two 
seminal studies then appeared simultaneously in the literature describing the use of 
essentially the same immunoprecipitation-based method to map m6A modifications in the 
transcriptome (2,3). The approach consisted of fragmenting cellular RNA into small pieces 
and then using an antibody specific for the methylated base to immunoprecipitate m6A-
containing fragments. Libraries were then prepared from the purified RNAs for high-
throughput sequencing on a Next-Generation-Sequencing (NGS) platform. Although the 
m6A sites could in reality be located anywhere within the sequenced reads, computational 
algorithms were used to predict the likely methylation site. Importantly it was also found by 
both studies that most of the RNA fragments mapped to within close vicinity of the stop 
codon of mRNAs, although the mechanistic significance of this finding remains to be 
determined.  
An additional study published in 2012 also reported transcriptomic identification of m5C 
using bisulfite sequencing (4), which had been used previously to detect DNA m5C 
modifications. The authors optimised the protocol so that RNA could seemingly withstand 
the harsh chemical conditions of the bisulfite treatment. The analysis revealed widespread 
occurrence of the modification in several RNA biotypes, including mRNAs as previously 
predicted by Dubin and Taylor (1975) (1).  The integrity of the RNA libraries following 
bisulfite treatment however could not be fully assessed and the method also does not 
enrich for modified RNA sites, as in the m6A-immunoproecptitaion protocol, meaning that 
methylation-site detection and calling was likely sub-optimal. Independent approaches were 
also clearly necessary and were provided by two studies again appearing fortuitously in 
quick succession in the literature which described distinct but related cross-linking 
immunoprecipitation (CLIP)-based techniques for detecting m5C RNA modifications (5,6).  
Initially described for the use of detecting protein-RNA interactions, efficient CLIP-based 
techniques employed UV covalent crosslinking to enable the RNA interaction partners of a 
protein of interest to be identified with high stringency and at a remarkably high signal to 
noise ratio (13,14). The methylation of m5C RNA is catalysed via a covalent catalytic 
intermediate between the RNA methylase enzyme and RNA substrate: if these catalytic 
intermediates could be frozen or ‘trapped’, they could be immunoprecipitated to detect the 
RNA methylation sites. Khoddami and Cairns (2013) described their 5-azacytidine-mediated 
RNA immunoprecipitation (Aza-IP) approach where they employed the cytidine nucleoside 
analogue 5-azacytidine (5), which becomes incorporated into DNA and RNA during 
replication and transcription respectively. m5C DNA and RNA methylases will methylate 
cytosine residues as well as 5-azacytosine residues via a covalent catalytic intermediate, but 
when they methylate the latter, the resolution of the covalent adduct cannot take place due 
to the altered chemistry of the nucleobases. Thus cells treated with 5-Azacytidine enabled 
CLIP-based experiments to be performed where an antibody against an epitope-tagged m5C 
RNA methylase was used to immunoprecipitate the frozen catalytic intermediates, enabling 
identification of the methylation substrates. In CLIP experiments, during the cDNA synthesis 
step of the library preparation, mutations in the sequence are incorporated as the reverse 
transcriptase traverses the crosslink site; these crosslink-induced mutation sites (CIMS) are 
estimated to occur at a frequency of ~8-20% of reverse transcription events, and their 
presence can be used to pinpoint the crosslink/interaction site (15). Similarly, in the Aza-IP 
libraries, it was observed that the sequence reads often also contained CIMS at the 
crosslink/methylation site and hence these could be used to infer the methylation site at 
nucleotide resolution (5).  
Aza-IP involves altering the physiology of cells by requiring a 12 hour pre-incubation with 
the cytotoxic agent 5-azacytidine, which is known to lead to hypomethylation of DNA even 
at low doses, and its effect of the nucleoside analogue following incorporation into different 
RNA species are not fully characterised but may interfere with RNA translation and 
metabolism. Further, more than 80% of reverse transcription events are estimated to stall at 
the protein-RNA crosslink site during cDNA synthesis, rather than reading through the 
crosslink site (16); in CLIP-based techniques, these truncated cDNAs are lost during NGS 
library preparation as they lack the terminal adapter sequence required for PCR 
amplification. This is overcome by the individual-nucleotide resolution crosslinking 
immunoprecipitation (iCLIP) method, which was developed to enable amplification of such 
truncated cDNAs (17). In iCLIP, the last nucleotide of the truncated cDNAs can be used to 
identify the crosslink site with increased efficiency (16,17). The methylation-iCLIP (miCLIP) 
technique developed in Hussain et al. 2013a describes a customised version of iCLIP (6) that 
takes advantage of a mutation within the key cysteine residue of m5C RNA methylases that 
is required for resolution of catalytic intermediates (18,19,20) (Figure 1). Substitution of this 
catalytic cysteine to alanine led to effective trapping of catalytic intermediates, which 
enabled to crosslink the methylases to its endogenous RNA targets without the need of 
photocrosslinking. These crosslinked epitope tagged enzyme-substrate covalent adducts are 
then immunoprecipitated, the cDNA library is prepared using the iCLIP protocol, and the 
positions of cDNA truncations identified the m5C methylation sites with nucleotide-
resolution.  
The miCLIP study demonstrated that identified m5C substrates were likely of biological 
relevance. For example, miCLIP for the NSun2 m5C RNA methylase detected methylation 
sites at various nucleotide positions within the Vault ncRNAs; these were then confirmed by 
performing bisulfite sequencing of Vault ncRNA extracted from cells obtained from human 
patients with NSun2-deficiency syndromes (6). The study also showed that the methylation 
events mechanistically impacted on the processing of Vault hairpin RNAs into small RNAs 
with microRNA-like function. Importantly there are six other members of the NSun family of 
m5C RNA methylases which should also be amenable to miCLIP (Figure 1). 
Recently, a further iCLIP-based technique was developed in order to identify m6A sites at 
nucleotide resolution in transcriptomes (21). The technique involves incubation of a m6A-
antibody with purified cellular RNA followed by in vitro UV-crosslinking. These crosslinked 
antibody-RNA complexes are then immunoprecipitated, the cDNA library is prepared using 
the iCLIP protocol, and the positions of cDNA truncations identified the m6A methylation 
sites with nucleotide-resolution. The procedure was named m6A-iCLIP and abbreviated to 
miCLIP. To allow a broader use of this term, we suggest that miCLIP is described as 
methylation-iCLIP, which can then be applied both for cases where protein-RNA complexes 
are crosslinked within intact cells (6) or purified RNA (21) in order to identify sites of RNA 
methylation. 
 
1.2 An overview of m5C-iCLIP  
The aforementioned work (2,3,4,5,6,21) as well as important studies that have also 
described novel transcriptomic techniques to detect other types of RNA modifications 
(22,23,21) have set the stage for ‘epitranscriptomics’. This area of research concerns the 
sequence-context specific characterisation and investigation of RNA modifications in 
complex transcriptomes (24,25,26). Methylation-iCLIP will continue to play an important 
role in this fledgling field, and in this chapter we describe the m5C-iCLIP protocol. In classic 
iCLIP experiments, UV crosslinking is required to introduce covalent crosslinks between 
proteins and interacting RNAs; this step is omitted from the miCLIP protocol. Instead 
expression of a point-mutant form of an RNA methylase of interest is required which will 
lead to RNA substrate trapping; we have previously and are currently performing this using 
point mutant forms of the NSun family of RNA m5C methylases. Experiments can be 
performed by transfecting suitable expression vectors into cells which also offers the 
advantage that an antibody against an epitope tag can be used for immunoprecipitation. 
Genome editing methods however, may also potentially be used in order to achieve 
endogenous expression of the point mutant. Following expression, cells are lysed and the 
enzyme-substrate covalent adducts are recovered by immunoprecipitation; the use of a 
good, highly specific antibody is key to the experiment and we generally recommend using 
an antibody against an epitope tag. A multi-step library preparation procedure is then 
employed which is designed to enable methylation sites to be determined at nucleotide 
resolution following sequencing of prepared libraries on an NGS platform. Bioinformatics 
analysis of recovered data can be performed by using the online PIPE-CLIP tool (27). As in 
iCLIP, the primers used for cDNA synthesis during library prep contain a randomised barcode 
(often referred to as unique molecular identifiers or UMIs), which allow individual cDNAs to 
be counted during analyses, thus yielding a reliable quantitative estimate of crosslinking 
efficiencies at each nucleotide.  
 
2 Materials 
2.1 Cell culture and transfection 
1. HEK293 cells. 
2. Growth medium: Dulbecco’s Modified Eagles Medium (DMEM), 10% Fetal Bovine Serum, 
Penicillin-Streptomycin. 
3. Trypsin-EDTA: 1x solution 
4. Phosphate Buffered Saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4 
5. Lipofectamine 2000 
 
2.2 Immunoprecipitation and linker ligation 
1. Protein G or A magnetic Dynabeads  
2. RNase I: 100 U/µL 
3. High RNase: 1:50 dilution of RNaseI 
4. Low RNase: 1:1000 dilution of RNaseI 
5. Turbo DNase: 2 U/µL 
6. T4 PNK (with 3′ phosphatase activity) plus 10x PNK buffer 
7. RNasin: 20-40 U/µL 
8. T4 RNA Ligase I: 30 U/µL 
9. PEG400 
 
2.3 SDS PAGE analysis and nitrocellulose transfer 
1. ATP [γ-32P], 10mM; Activity: 3000Ci/mmol  
2. NuPAGE loading buffer  
3. 4-12% NuPAGE Bis-Tris gel 
4. NuPAGE MOPS SDS running buffer 
5. Pre-stained protein marker 
6. Nitrocellulose membrane 
7. Autoradiography cassette 
8. X-ray film 
 
2.4 Library preparation 
1. Proteinase K: 20 mg/mL 
2. Phenol-chloroform (24:23 v/v) 
3. Phase-lock gel heavy tubes 
5. Glycoblue: 15mg/ml 
6. Sodium acetate solution: 3 M in water, pH 5.5 
7. Superscript III reverse transcriptase and 5 x RT buffer (Life Technologies) 
8. dNTP mix: 10 mM dATP, 10 mM dTTP, 10 mM dCTP, 10 mM dGTP 
9. DTT solution: 0.1 M in water 
10. RNase I: 100 U/µL 
11. TBE-Urea loading buffer, 2x (Thermofisher Scientific)  
12. 6% TBE-Urea polyacrylamide gel 
13. Costar SpinX columns 
14. Glass pre-filters 
15. CircLigase II enzyme  and 10 x CircLigase II buffer (Epicentre) 
16. FastDigest BamHI enzyme and 10 x FastDigest Buffer  
17. P5/P3 solexa primer mix: 10 μM each primer 
18. Accuprime Supermix (Life Technologies) 
19. 6% TBE polyacrylamide gel 
20. SYBR green I, 10,000x (Thermofisher Scientific) 
 
2.5 Buffers 
1. Lysis buffer: 50 mM Tris–HCl, pH 7.4, 100 mM NaCl, 1 % Igepal CA-630, 0.1 % SDS.  
2. High-salt wash buffer: 50 mM Tris–HCl, pH 7.4, 1 M NaCl, 1 mM EDTA, 1 % Igepal CA-630, 
0.1 % SDS. 
3. PNK buffer: 20 mM Tris–HCl, pH 7.4, 10 mM MgCl2, 0.2 % Tween-20.  
4. 5× PNK pH 6.5 buffer: 350 mM Tris–HCl, pH 6.5, 50 mM MgCl2, 25 mM dithiothreitol 
(DTT). 
5. 4× ligation buffer: 200 mM Tris–HCl, pH 7.8, 40 mM MgCl2, 40 mM dithiothreitol (DTT). 
6. PK buffer: 100 mM Tris–HCl, pH 7.4, 50 mM NaCl, 10 mM EDTA. 
7. PK buffer-7M Urea buffer: 100 mM Tris–HCl, pH 7.4, 50 mM NaCl, 10 mM EDTA, 7 M urea 
8. TE Buffer: 10 mM Tris, 1mM EDTA, pH8 
 
2.6 Oligonucleotides 
1. Pre-adenylated linker (L3-App): rApp/AGATCGGAAGAGCGGTTCAG/ddC, 20µM; rApp = 
adenylation, ddC = dideoxycytidine (Note 1). 
2. RT primers (Note 2): 10 µM each 
Rt1clip/5Phos/NNAACCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt2clip/5Phos/NNACAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt3clip/5Phos/NNATTGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt4clip/5Phos/NNAGGTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt6clip/5Phos/NNCCGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt7clip/5Phos/NNCTAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt8clip/5Phos/NNCATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt9clip/5Phos/NNGCCANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt11clip/5Phos/NNGGTTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt12clip/5Phos/NNGTGGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt13clip/5Phos/NNTCCGNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt14clip/5Phos/NNTGCCNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt15clip/5Phos/NNTATTNNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
Rt16clip/5Phos/NNTTAANNNAGATCGGAAGAGCGTCGTGgatcCTGAACCGC 
N = random nucleotides. 
3. BamHI-cut-oligo (GTTCAGGATCCACGACGCTCTTCaaaa): 10 µM 
4. Illumina PCR primers: 10 µM each 
P5Solexa: AATGATACGGCGACCACCGAGATCTACACT CTTTCCCTACACGACGCTCTTCCGATCT  
P3Solexa: 
CAAGCAGAAGACGGCATACGAGATCGGTCTCGGCATTCCTGCTGAACCGCTCTTCCGATCT 
 
3. Methods 
3.1 Cell culture and transfection 
1. In a 10 cm dish, grow HEK293 cells in growth medium in a humidified incubator with 5% 
CO2 until they reach 50-70% confluence.  
2. Use Lipofectamine 2000 (Life Technologies) to transfect cells with mammalian expression 
vector encoding the RNA methylase of interest harbouring the substrate trapping point 
mutation (Note 3) and incubate cells for 24 hours. 
3. Following incubation, wash cells twice in PBS. Disperse cells by incubating cells for 1 
minute in Trypsin-EDTA and then add 30 mL of growth medium.  
4. Collect cells by centrifugation and then wash twice more in PBS via centrifugation and 
resuspension of cell pellet.  
5. Transfer cells in 1 mL PBS to microcentrifuge tubes, and subject to centrifugation to pellet 
cells for a final time. Cell pellets may be used immediately or frozen at -80oC for later use.  
 
3.2 Immunoprecipitation 
All subsequent steps in the protocol should be performed on wet ice unless otherwise 
stated. 
3.2.1 Dynabead preparation 
1. Transfer 100 μL of resuspended magnetic dynabeads (Note 4) to two 1.5 mL microtubes 
and label one ‘High RNase and the other ‘Low RNase’. Also repeat this for a no-antibody 
control sample. 
2. Wash the beads twice with 1 mL of lysis buffer. 
3. After the last wash, resuspend the beads in 500 μL of lysis buffer and then add 5-10 μg of 
antibody. 
4. Rotate tubes for 30 min at room temperature. 
5. Wash beads 5 times with 1 mL lysis buffer and leave in last wash until ready to proceed to 
step 3.2.3. 
3.2.2 Lysis and partial RNA digestion 
1. Add 1mL of cold lysis buffer to cell pellet, and then pipette to resuspend cell pellet. 
Incubate on ice for 30 mins and syringe lysate through a 19 gauge needle every 10 mins 
during the incubation.  
2. Add 10 μL of high or low RNase (Note 5) to the corresponding tube and 2 μL Turbo DNase 
to the cell lysate and then place the samples into a thermomixer set at 37 °C for 3 min, 
shaking at 1100 rpm. Following the 3 min incubation immediately transfer the microtube 
onto wet ice and leave for at least 3 min. 
3. Centrifuge for 20 min at 20,000xg at 4 °C and then transfer the supernatant to a 1.5mL 
microtube. The remaining pellet can be discarded. 
3.2.3. Immunoprecipitation 
1. Add the clarified lysate to the beads from step 3.2.1 and then rotate for 2-3 hours at 4oC.  
2. Use a magnetic rack to collect the dynabeads, discard the supernatant, and then wash the 
beads twice with 1 mL high salt wash buffer. 
3. Wash 3 more times with 1 mL PNK buffer for each wash and discard the supernatant from 
the final wash. 
3.3 RNA 3’ dephosphorylation 
1. Resuspend beads to homogeneity in 20 μL 3’ dephosphorylation mix containing 4 μL 5× 
PNK pH 6.5 buffer, 0.5 μL PNK (with 3′ phosphatase activity), 0.5 μL RNasin, 15 μL water. 
2. Incubate for 20 min at 37 °C in a thermomixer at 1100 rpm. 
3. Remove from thermomixer and add 1 mL of PNK buffer to wash beads. Perform 4 further 
washes in 1 mL PNK buffer. 
 
3.4 Preadenylated L3 adapter ligation 
1. Remove the supernatant and resuspend the beads in 20 μL adapter ligation mix 
containing 8 μL water, 5 μL 4× ligation buffer, 1 μL T4 RNA ligase, 0.5 μL RNasin, 1.5 μL pre-
adenylated linker L3-App, 4 μL PEG400. 
2. Incubate overnight at 16 °C in a thermomixer at 1100 rpm. 
3. Remove from thermomixer and add 1 mL of PNK buffer to wash beads. Perform 4 further 
washes in 1 mL PNK buffer, and then leave in 1 mL of PNK buffer. 
 
3.5 RNA 5’ end labelling 
1. Transfer 200 μL of the resuspended beads (the remaining 800 μL will be used in step 4) to 
a new RNAse free microtube and remove the supernatant.  
2. Resuspend beads in 10 μL of radioactive PNK mix containing 0.5 μL PNK, 1 μL 32P-γ-ATP, 1 
μL 10× PNK buffer, 7.5 μL water. 
3. Incubate for 5 min at 37oC and then discard the supernatant as radioactive waste. 
4. Resuspend beads in 20 μL 1 x NuPAGE loading buffer and add this to the remaining cold 
beads from section 3.4, step 3, following removal of the supernatant from them. 
6. Incubate for 5 min at 80oC. 
7. Place back on the magnet and collect the supernatant which will be loaded directly onto 
the gel in the next step. 
3.6 SDS–PAGE and nitrocellulose transfer 
1. Load the samples on a 4–12% NuPAGE Bis-Tris gel. .Also load 5 μL of a pre-stained protein 
size marker. Use 0.5 L 1x NuPAGE MOPS SDS running buffer. 
2. Run the gel at 180 V for 50 min and once complete, cut off the foot of the gel containing 
the dye front and discard it as solid radioactive waste. 
3. Transfer the protein–RNA complexes from the gel to a nitrocellulose membrane at 30V 
for 1 hour. 
4. Once the transfer is complete, wrap the nitrocellulose membrane in saran wrap and fix it 
into an autoradiography cassette which contains a fluorescent marker. 
5. Expose the membrane to an X-ray film and then transfer the cassette into a −80 °C 
freezer. Exposures can be performed for 30 min, 1 h and overnight. 
 
3.7 Library preparation 
3.7.1 RNA isolation 
1. Use the fixed fluorescent marker in the autoradiography cassette to re-align the 
processed film and then mark the area of the nitrocellulose membrane that contains the 
protein-RNA complex smear in the low RNase condition (Note 6). Using a sharp blade, 
carefully cut out this region of nitrocellulose, dissect further into small pieces, and then 
transfer them to a RNase free 1.5 mL microtube.  
2. Add 10 μL proteinase K in 200 μL PK buffer to the nitrocellulose fragments so that they 
are all submerged. Transfer tubes to a thermomixer and incubate for 20 min shaking at 
1100 rpm at 37 °C. 
3. Add 200 μL of PK buffer-7 M urea and incubate for further 20 min at 37 °C and 1100 rpm. 
4. Collect the solution and add it to a 2 mL Phase Lock Gel Heavy tube. Add 400 μL 
phenol/chloroform and then incubate in a thermomixer for 5 min at 30 °C shaking at 
1100 rpm.  
5. Separate the phases by spinning for 5 min at 20,000xg and room temperature. 
6. Transfer the aqueous layer into a non-stick RNase free 1.5 mL microfuge tube and add 
1 μL glycoblue and 40 μL sodium acetate solution. Mix and then add 1 mL 100% ethanol. 
Mix again and then place at −20 °C overnight. 
7. Centrifuge at 20,000g at 4 °C for 20 min and then remove the supernatant. Wash the 
pellet with 1 mL 80% ethanol and spin again for 5 min. Resuspend the pellet thoroughly in 
5 μL H2O and transfer to an RNase free PCR tube. 
 
3.7.2 Reverse transcription 
1. Add 1 μL of RT primer (Note 7) and 1 μL dNTP mix to the resuspended pellet and then 
incubate in a thermocycler set to the following programme: 70 °C for 5 min, then hold at 25 
°C until the RT mix is added next. 
2. Add 13 μL of the RT mix containing 7 μL H2O, 4 μL 5× RT buffer, 1 μL DTT, 0.5 μL RNasin, 
0.5 μL Superscript III reverse transcriptase, transfer tube to a thermal cycler and perform 
the reverse transcription with the following program: 25 °C for 5 min, 42 °C for 20 min, 50 °C 
for 40 min, 80 °C for 5 min, then hold at 4 °C. 
3. Once the RT program is complete, add 350 μL TE buffer, 1 μL GlycoBlue and 40 μL sodium 
acetate pH 5.5. Mix, and then add 1 mL 100 % ethanol. Mix again and precipitate overnight 
at −20 °C. 
 
3.7.3 Gel purification (Note 8) 
1. Centrifuge for 20 min at 20,000xg at 4 °C. Remove the supernatant and add 1 mL 80% 
ethanol. Repeat centrifugation, remove supernatant and then resuspend the pellet in 6 μL 
H2O. 
 
2. Add 6 μL 2 × TBE-urea loading buffer to the samples and also to 6 μL DNA size marker. 
Heat samples at 70 °C for 2 min immediately before loading onto a 6% TBE-urea gel (Life 
Technologies). 
3. Run gel in 1X TBE buffer for 40 min at 180 V until the lower dye is close to the bottom. 
4. Cut off the last lane containing the size marker and incubate it in 20 mL 1X TBE buffer 
with 2 μL SYBR green II for 10 min. Wash the gel twice with 1XTBE and visualize by UV 
transillumination. Print the result with 100% scale, and use it as a mask to guide the excision 
of cDNA bands from the rest of the gel. 
5. Together with the preadenylated L3 adapter sequence, the primer sequence accounts for 
52 nt of the cDNA. Cut three bands, at 70–80 nt, 80–150 nt and 150-200 nt and transfer 
them each to a non-stick RNase free 1.5 mL microtube (Note 9). 
6. Add 400 μL TE buffer to the gel piece and crush it into tiny pieces with a 1 mL pipette tip. 
7. Transfer to a thermomixer and incubate with shaking at 1100 rpm for 1h at 37 °C. Then 
place on dry ice for 5 min, and then place back for 1 h at 1100 rpm at 37 °C in the 
thermomixer.  
8. Transfer the liquid portion of the supernatant into a Costar SpinX column into which you 
have placed two 1 cm glass pre-filters. 
9. Centrifuge at 20,000xg for 1 min at room temperature and transfer the flow-through to a 
non-stick RNase free 1.5mL microtube. 
 
10. Add 1 μL glycoblue and 40 μL sodium acetate solution and mix. Add 1 mL 100% ethanol, 
mix again and precipitate at −20 °C overnight. 
 
3.7.4 cDNA circularisation (Note 10) 
1. Centrifuge for 20 min at 20,000xg at 4 °C. Remove the supernatant and add 1 mL 80% 
ethanol. Repeat centrifugation, remove supernatant and then resuspend the pellet in 8 μL 
ligation mix containing 6.5 μL water, 0.8 μL 10× CircLigase Buffer II, 0.4 μL 50 mM MnCl2, 0.3 
μL CircLigase II. Transfer the mix to nuclease-free PCR tubes and incubate for 1 h at 60 °C. 
 
2. Add 30 μL oligonucleotide annealing mix: 26 μL H2O, 3 μL FastDigest Buffer, 1 μL BamHI 
Cut_oligo and anneal in a thermal cycler using the following program: 95 °C for 2 min; then 
successive cycles of 20 s, starting from 95 °C and decreasing the temperature by 1 °C each 
cycle down to 25 °C; then hold at 25 °C. 
 
3. Add 2 μL FastDigest BamHI enzyme and incubate for 30 min at 37 °C, followed by an 
incubation at 80 °C for 5 min.  
 
4. Add 350 μL TE, 1 μL GlycoBlue, 40 μL sodium acetate solution and mix. Then add 1 mL 100 
% ethanol, mix again and precipitate overnight at −20 °C. 
 
3.8 PCR amplification and library submission 
 
1. Centrifuge for 20 min at 20,000xg at 4 °C. Remove the supernatant and add 1 mL 80% 
ethanol. Repeat centrifugation, remove supernatant and then resuspend the pellet in 20 μL 
H20 and transfer to PCR tube. 10 μL of this will be used in the PCR in the next step and the 
remainder can be stored at −20 °C for further future use if necessary. 
2. Prepare the PCR mix as follows: 10 μL cDNA, 1 μL primer mix of P5Solexa and P3Solexa, 
20 μL Accuprime Supermix, 9 μL H2O. 
3. Place tube in thermal cycler and run the following program: 94 °C for 2 min, followed by 
25 cycles of: 94 °C for 15 s, 65 °C for 30 s, 68 °C for 30 s; complete with 68 °C for 3 min, then 
hold at 25 °C. 
4. Once the program is complete, mix 8 μL PCR product with 2 μL 5x TBE loading buffer, load 
on a 6% TBE polyacrylamide gel and run at 180 V and 120 mA for 30 min. Stain and visualize 
with SYBR green I (Note 11). 
5. PCR amplified miCLIP libraries can then be quantified using a Qubit fluorometer (Life 
Technologies).  
6. Dilute libraries to 10 nM, or to a sequencing facility-specified concentration, and 
sequence using 50nt single or paired-end runs on an Illumina sequencer. We have routinely 
performed sequencing on the GAII and also the MiSeq platform to generate sufficient 
RNAseq reads.  
7. Bioinformatics analysis may be performed using the online PIPE-CLIP tool (27). 
 
 
Notes 
1. Pre-adenylation (rApp) of the DNA linker is required for efficient ligation to the 3’-OH 
group of RNAs. The dideoxycytidine group (ddC) is added to the 3’ end of the 
adenylated linker in order to prevent circularisation. 
2. The 5’end of each primer contains a 9-nucleotide barcode consisting of 2 random 
nucleotides (N) followed by a 4-nucleotide fixed barcode and finished off with 3 
more random nucleotides. The fixed barcode allows multiplexing of replicates or 
samples, which is important to reduce the costs of the downstream next generation 
sequencing. The random barcode allows for tracing and counting of individual cDNA 
synthesis events, thus avoiding the overrepresentation of abundant RNAs which 
would otherwise be encountered by analysing exponentially amplified PCR product. 
The last 9 nucleotides of the RT primers have sequence complementarity to the final 
9 nucleotides of the L3-App linker. 
3. Enzymes that catalyse RNA modification via a two-step catalytic process as described 
in Figure 1 will be amenable to methylation-iCLIP. Several enzymes have been 
described which are known to catalyse RNA modifications via a covalent 
intermediate (28), however the biochemical mechanisms via which these adducts 
are resolved are often poorly defined. It is possible that amino acid residues within 
the catalytic domain are critical for resolution, as is observed in the NSun family of 
RNA m5C methylases, but these will require identification for each particular enzyme 
before methylation-iCLIP can be performed. 
4. Generally, protein G for mouse antibodies, and protein A for rabbit antibodies is 
used. 
5. RNA digestion conditions will need to be pre-optimised for each protein-RNA 
complex under study. We initially recommend using a 1:50 dilution of RNaseI for 
‘high RNase’ and a 1:1000 dilution for ‘low RNase’. High RNase treatment should 
result in a sharp band around the expected molecular weight of your RNA methylase 
of interest during the SDS-PAGE analysis (step 3.6), whereas the low RNase 
treatment should result in a smear above the expected molecular weight of the 
protein. 
6. The high RNAse sample is only used in the protocol in order to check for the 
presence of the desired protein-RNA complex following immunoprecipitation, but is 
not used to prepare libraries as the RNAs would be too short in length to map 
uniquely to the genome. The RNAs present in the higher molecular weight smear in 
the low RNase condition are thus used for library preparation only. 
7. A distinct RT primer (one of Rt1clip to Rt16clip) can be used for each of several 
replicates or samples if desired. The barcode on these RT primers (see note 2) will 
then allow for multiplexing of samples thus enabling the cost of next-generation-
sequencing to be managed. 
8. Gel purification is necessary to remove residual RT primer and also for size 
fractionation of cDNAs (see note 9).  
9. The band cut at 70-80nt will contain a cDNA insert size of 18-28nt; this band usually 
consists of a high cDNA complexity, but due to the small size of inserts they do not 
always map to the genome. If the RNA methylase of interest is suspected to 
methylate microRNAs, then this band should be included for sequencing. The band 
cut at 80-150nt will contain insert sizes of 29-98nt with a high cDNA complexity; 
these cDNAs will also map uniquely to the genome and are the best cDNAs. The band 
cut at 150nt-200nt will contain insert sizes of 98-148nt but this fraction tends to 
consist of a limited cDNA complexity.  
10. Most cDNA synthesis events will truncate at the crosslink site thus allowing the 
methylation site to be subsequently determined. In order to achieve PCR 
amplification of these cDNAs however, ligation of a 5’ terminal adapter is required. 
This is achieved by performing a cDNA circularisation followed by a BamHI digestion 
of a restriction site originally located within the 3’terminal adapter (step 3).  This 
results in a portion of the 3’ adapter now being ligated to the 5’end, thus serving as a 
PCR priming site.  
11. The size of the cDNA insert will be the size of PCR product minus the combined 
length of the P3/P5Solexa primers and the barcode (128 nt). Thus for example, a 
band cut at 70–80 nt on the cDNA gel (with 18-28nt cDNA + 52 nt primer) will 
generate 146–156 nt PCR products. 
 
 
 
Figure legend 
Figure 1 
(A) Sequence alignment of a region of the catalytic domain of the seven known members of 
the human family of m5C RNA methylases. Two key conserved cysteine residues (Cys1 & 
Cys2) play critical roles in the methylation process. Identical residues in the alignment are 
indicated by asterix. (B) The conserved cysteine residue Cys1 forms a transient covalent 
bond (purple line) with the cytosine being methylated during the methylation process. A 
second cysteine Cys2 is then critical for the resolution of this covalent bond to complete the 
catalytic process (left). In methylation-iCLIP, Cys2 is mutated to alanine (right) which results 
in the capture of the catalytic intermediate where the methylase is covalently bound to its 
substrate. This complex can then be immunoprecipitated using an antibody against the 
methylase or an epitope tag, and the trapped RNAs are then amenable to purification under 
highly stringent conditions. Libraries prepared from recovered RNA substrates are then 
subjected to high-throughput sequencing. 
 
Acknowledgments  
We wish to acknowledge Dr Julian Konig who co-developed the original iCLIP protocol, and 
Dr Yoichiro Sugimoto for helpful feedback and discussions during the development of 
methylation-iCLIP. 
 
References  
1. Dubin DT, Taylor RH. (1975). The methylation state of poly A-containing messenger RNA 
from cultured hamster cells. Nucleic Acids Res. 2:1653-68. 
2. Dominissini, D., Moshitch-Moshkovitz, S., Schwartz, S., Salmon-Divon, M., Ungar, L., 
Osenberg, S., et al. (2012). Topology of the human and mouse m6A RNA methylomes 
revealed by m6A-seq. Nature 485, 201–206. 
3. Meyer, K. D., Saletore, Y., Zumbo, P., Elemento, O., Mason, C. E., and Jaffrey, S. R. (2012). 
Comprehensive analysis of mRNA methylation reveals enrichment in 3′ UTRs and near stop 
codons. Cell 149, 1635–1646. 
4. Squires, J. E., Patel, H. R., Nousch, M., Sibbritt, T., Humphreys, D. T., Parker, B. J., et al. 
(2012). Widespread occurrence of 5-methylcytosine in human coding and non-coding 
RNA. Nucleic Acids Res. 40, 5023–5033. 
5. Khoddami, V., and Cairns, B. R. (2013). Identification of direct targets and modified bases of 
RNA cytosine methyltransferases. Nat. Biotechnol.31, 458–464. 
6. Hussain, S., Sajini, A. A., Blanco, S., Dietmann, S., Lombard, P., Sugimot, Y., et al. (2013a). 
NSun2-mediated cytosine-5 methylation of vault noncoding RNA determines its processing 
into regulatory small RNAs. Cell Rep. 4, 255–261. 
7. Wang, X., Lu, Z., Gomez, A., Hon, G. C., Yue, Y., Han, D., et al. (2014). N6-methyladenosine-
dependent regulation of messenger RNA stability.Nature 505, 117–120.  
8. Wang, X., Zhao, B. S., Roundtree, I. A., Lu, Z., Han, D., Ma, H., et al. (2015). N(6)-
methyladenosine modulates messenger RNA translation efficiency. Cell 161, 1388–1399. 
9. Meyer KD, Patil DP, Zhou J, Zinoviev A, Skabkin MA, Elemento O, Pestova TV, Qian 
SB, Jaffrey SR. (2015). 5' UTR m(6)A Promotes Cap-Independent Translation. Cell. 163: 999-
1010.  
10. Hussain S, Bashir ZI. (2015) The epitranscriptome in modulating spatiotemporal RNA 
translation in neuronal post-synaptic function. Front Cell Neurosci. 9:420. 
11. Bokar, J. A., Shambaugh, M. E., Polayes, D., Matera, A. G., and Rottman, F. M. (1997). 
Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-
adenosine)-methyltransferase. RNA 3, 1233–1247. 
12. Jia, G., Fu, Y., Zhao, X., Dai, Q., Zheng, G., Yang, Y., et al. (2011). N6-methyladenosine in 
nuclear RNA is a major substrate of the obesity-associated FTO. Nat. Chem. Biol. 7, 885–887. 
13. Ule J, Jensen KB, Ruggiu M, Mele A, Ule A, Darnell RB. (2003) CLIP identifies Nova-regulated 
RNA networks in the brain. Science. 302:1212-5. 
14. Licatalosi DD, Mele A, Fak JJ, Ule J, Kayikci M, Chi SW, Clark TA, Schweitzer AC, Blume JE, 
Wang X, Darnell JC, Darnell RB. (2008) HITS-CLIP yields genome-wide insights into brain 
alternative RNA processing. Nature. 456:464-9.  
15. Zhang C, Darnell RB. (2011) Mapping in vivo protein-RNA interactions at single-nucleotide 
resolution from HITS-CLIP data. Nat Biotechnol. 29:607-14.  
16. Sugimoto Y., Konig J., Hussain S., Zupan B., Curk T., Frye M., Ule J. (2012) Genome 
Biol. 13:R67. 
17. König J, Zarnack K, Rot G, Curk T, Kayikci M, Zupan B, Turner DJ, Luscombe NM, Ule J. (2010) 
iCLIP reveals the function of hnRNP particles in splicing at individual nucleotide resolution. 
Nat Struct Mol Biol. 17:909-15.  
18. King, M.Y., and Redman, K.L. (2002). RNA methyltransferases utilize two cysteine residues in 
the formation of 5-methylcytosine. Biochemistry 41, 11218–11225. 
19. Redman, K.L. (2006). Assembly of protein-RNA complexes using natural RNA and mutant 
forms of an RNA cytosine methyltransferase. Biomacromolecules 7, 3321–3326. 
20. Hussain, S., Benavente, S.B., Nascimento, E., Dragoni, I., Kurowski, A., Gillich, A., Humphreys, 
P., and Frye, M. (2009). The nucleolar RNA methyltransferase Misu (NSun2) is required for 
mitotic spindle stability. J. Cell Biol. 186, 27–40 
21. Linder, B., Grozhik, A. V., Olarerin-George, A. O., Meydan, C., Mason, C. E., and Jaffrey, S. R. 
(2015). Single-nucleotide-resolution mapping of m6A and m6Am throughout the 
transcriptome. Nat. Methods 12, 767–772.  
22. Carlile, T. M., Rojas-Duran, M. F., Zinshteyn, B., Shin, H., Bartoli, K. M., and Gilbert, W. V. 
(2014). Pseudouridine profiling reveals regulated mRNA pseudouridylation in yeast and 
human cells. Nature 515, 143–146.  
23. Schwartz, S., Bernstein, D. A., Mumbach, M. R., Jovanovic, M., Herbst, R. H, León-Ricardo, B. 
X., et al. (2014). Transcriptome-wide mapping reveals widespread dynamic-regulated 
pseudouridylation of ncRNA and mRNA. Cell 159, 148–162. 
24. Saletore, Y., Meyer, K., Korlach, J., Vilfan, I. D., Jaffrey, S., and Mason, C. E. (2012). The birth 
of the epitranscriptome: deciphering the function of RNA modifications. Genome Biol. 13, 
175. 
25. Hussain, S., Aleksic, J., Blanco, S., Dietmann, S., and Frye, M. (2013b). Characterizing 5-
methylcytosine in the mammalian epitranscriptome. Genome Biol. 14, 215. 
26. Rinn, J. L., and Ule, J. (2014). Oming in on RNA–protein interactions. Genome Biol. 15, 401. 
27. Chen B, Yun J, Kim MS, Mendell JT, Xie Y. (2014) PIPE-CLIP: a comprehensive online tool for 
CLIP-seq data analysis. Genome Biol. 15:R18.  
28. Guelorget A and Golinelli-Pimpaneau B. (2011) Mechanism-based strategies for trapping and 
crystallizing complexes of RNA-modifying enzymes. Structure. 19:282–291. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1 
 
 
